Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sanofi pasteur europe - salmonella typhi ty2 vi kapselpolysaccharid - injektionsvæske, opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

novartis healthcare a/s - ondansetron - injektionsvæske, opløsning - 2 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - salmonella typhi ty2 vi kapselpolysaccharid - injektionsvæske, opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - salmonella typhi ty2 vi kapselpolysaccharid - injektionsvæske, opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

morningside healthcare (malta) limited - midodrinhydrochlorid - tabletter - 2,5 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegravir - hiv infektioner - antivirale midler til systemisk anvendelse - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 og 5.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatiske neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

guerbet - iobitridol - injektionsvæske, opløsning - 250 mg iod/ml